Personalized therapeutics and companion diagnostics: a new paradigm in testing and treatment.

نویسندگان

  • Nicholas E Heger
  • Mark D Kellogg
چکیده

Serum contains 1-transferrin, and CSF contains 1 and 2 transferrins. The 2-transferrin in CSF is desialylated because of the presence of neuraminidase in the central nervous system. Hence, 2-transferrin is used as a marker of CSF leakage (1 ). Because 1-transferrin was present in serum but absent in drainage fluid, additional neuraminidase activity was suspected. This suspicion was supported by the culture of Staphylococcus aureus from the fluid. Most S. aureus strains have neuraminidase activity (2 ), and sepsis is associated with decreased sialylation of circulating transferrin (3 ).

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics

Rapid innovation in (epi)genetics and biomarker sciences is driving a new drug development and product development pathway, with the personalized medicine era dominated by biologic therapeutics and companion diagnostics. Companion diagnostics (CDx) are tests and assays that detect biomarkers and specific mutations to elucidate disease pathways, stratify patient populations, and target drug ther...

متن کامل

Precision medicine, technologies, and molecular diagnostics

Introduction: Genetics, cellular and molecular medicines are cutting-edge sciences and technologies that play an important role in improving human health and quality of life. In addition, medical and biological sciences have clearly shown that the onset of diseases differs from person to person due to their different genetic profiles and variations in molecular basis. Therefore, it is feasible ...

متن کامل

Personalized Medicine’s Bottleneck: Diagnostic Test Evidence and Reimbursement

BACKGROUND Personalized medicine is gradually emerging as a transformative field. Thus far, seven co-developed drug-diagnostic combinations have been approved and several dozen post-hoc drug-diagnostic combinations (diagnostic approved after the drug). However, barriers remain, particularly with respect to reimbursement. Purpose, methods: This study analyzes barriers facing uptake of drug-diagn...

متن کامل

Challenges in the codevelopment of companion diagnostics

The goal of personalized medicine, to effectively customize diagnosis, treatment and prevention of disease to one’s genetic composition, is one that has been known and sought for many years. Increasingly, molecular companion diagnostics based on one’s inherited or somatic biomarkers are desired to ensure the effective, safe develop­ ment and application of a personalized drug. This has been ref...

متن کامل

Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics—Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer

Companion diagnostics (CDx) have become a major tool in molecular pathology and assist in therapy decisions in an increasing number of various cancers. Particularly, the developments in lung cancer have been most impressing in the last decade and consequently lung cancer mutation testing and molecular profiling has become a major business of diagnostic laboratories. However, it has become diffi...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Clinical chemistry

دوره 60 5  شماره 

صفحات  -

تاریخ انتشار 2014